Biotechnology company Revance Therapeutics Inc (Nasdaq:RVNC) stated on Tuesday that it plans to start an underwritten public offering of its common stock.
Net proceeds from the planned offering of common stock may be used by the company to continue to fund the commercialisation of DAXI, working capital, research and development as well as general corporate purposes.
Subject to market and other conditions, the company said there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Cowen, Piper Jaffray & Co and Stifel are acting as book-running managers for the proposed offering.
Revance Therapeutics develops next-generation neuromodulators for treating aesthetic and therapeutic conditions.
Romark starts phase three clinical trial of COVID-19 drug NT-300
Brazilian state of Paraná to sign agreement with Russia for testing COVID-19 vaccine
US government signs USD1.525bn deal with Moderna for 100 million doses of its COVID-19 vaccine
XPRIZE Pandemic Alliance, New England Complex Systems Institute Forge COVID-19 CT Scan Collaborative
Russia's "Sputnik V" COVID-19 vaccine in demand by 20 countries